Zur Startseite
Muhammed Mustafa Atci
14
Jahre der Erfahrung

Muhammed Mustafa Atci

  • Spezialisierung: Klinischer Onkologe/-in
  • 14 Jahre der Erfahrung
  • Spricht:
    English, Turkish
  • Online-Konsultationen: verfügbar
  • Arbeitsplatz: Türkei, Istanbul, İstinye University Liv Hospital Topkapı
  • Mitglied der Amerikanischen Gesellschaft für Klinische Onkologie (ASCO) seit 2018.

    Dr. Muhammed Mustafa Atci ist außerordentlicher Professor für Medizinische Onkologie an der İstinye-Universität, Liv Hospital Topkapı (seit 2025). Zuvor war er als außerordentlicher Professor und Weiterbildungskoordinator am Prof.-Dr.-Cemil-Taşcıoğlu-Stadtkrankenhaus tätig (2023–2025). Davor war er dort als Medizinischer Onkologe tätig (2018–2021).

    Seit 2018 ist er Mitglied der ASCO und der Türkischen Gesellschaft für Medizinische Onkologie. Er ist Autor oder Koautor von 19 begutachteten internationalen Fachartikeln zu Kolon-, Brust-, Magen-, Pankreas-, Lungen-, Schilddrüsen-, Sarkom- und kolorektalen Krebsarten.

    Zu seinen bemerkenswerten Arbeiten gehört eine multizentrische Studie zum Überleben beim Kolonkarzinom im Stadium IIB (Journal of Chemotherapy). Außerdem untersuchte er das De‑Ritis‑Verhältnis im Hinblick auf Lungenmetastasen bei Hodenkrebs (Current Urology). In seinen prognostischen Studien nutzte er PET/CT, MSI, den Lymphknotenquotienten und das metabolische Tumorvolumen.

Online-Konsultation bei Muhammed Mustafa Atci

Bequem und einfach
100% sicher und vertraulich
Preis auf Anfrage

Dienstleistungen des Arztes

Mehr anzeigen

Wie läuft es für Sie mit uns?

1 von 3
Die Informationen über diesen Arzt sind vollständig und klar
1
2
3
4
5
Stimme nicht zu
Stimme stark zu

Qualifikationen

Education

Doctor of Medicine (M.D.)
2003 – 2009
Istanbul University – Cerrahpaşa Faculty of Medicine, Turkey

Residency in Internal Medicine
2011 – 2015
University of Health Sciences – Istanbul Şişli Hamidiye Etfal Health Application and Research Center, Department of Internal Medicine, Turkey

Professional Experience

Internal Medicine Specialist
2015 – 2017
Tokat State Hospital, Turkey

Internal Medicine Specialist
2017 – 2018
Istanbul Haseki Training and Research Hospital, Turkey

Medical Oncologist
2018 – 2021
University of Health Sciences – Istanbul Prof. Dr. Cemil Taşcıoğlu City Health Application and Research Center, Department of Internal Medicine / Oncology Department, Turkey

Associate Professor of Medical Oncology & Education Coordinator
2023 – 2025
Ministry of Health – Prof. Dr. Cemil Taşcıoğlu City Hospital, Turkey

Education Coordinator for the Medical Oncology Sub-Branch

Associate Professor of Medical Oncology
2025 – Present
İstinye University, Liv Hospital Topkapı, Turkey

Memberships to Scientific Organizations

American Society of Clinical Oncology (ASCO) – Member since 2018

Turkish Society of Medical Oncology – Member since 2018


Articles Published in Peer-Reviewed International Journals

1. Atcı, M. M., Akagündüz, B., Demir, M., Arıkan, R., Ay Ersoy, S., Özer, M., Ayhan, M., Çil, İ., Demir, N., Özyurt, N., Karakaya, G., Çevik, G. T., Önder, A. H., Selvi, O., Sakin, A. (2023). The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. Journal of Chemotherapy.

2. Bozkurt, M., Aghalarov, S., Atcı, M. M., Selvi, O., Canat, H. L. (2022). A new biomarker for lung metastasis in non-seminomatous testicular cancer: De Ritis Ratio. Current Urology.

3. Dülgar, Ö., Öven, B. B., Atcı, M. M., Arıkan, R., Ay Ersoy, S., Ayhan, M., Selvi, O., Tataroğlu Özyükşeler, D., Bayram, E., Özcan, E., Yasin, A. İ., Gümüş, M. (2022). Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Review of Anticancer Therapy.

4. Akagündüz, B., Altın, Z., Atcı, M. M., Özer, M., Güven, D. C., Çil, İ., Özçiçek, F., Demirtaş, L., Düzgün, E., Gunderci, A., Arslan, Y. (2021). Assessment of abuse and related factors in older patients with cancer. Supportive Care in Cancer.

5. Akagündüz, B., Özer, M., Karaçin, C., Atcı, M. M., Yıldırım, H. Ç., Ünver, E. (2021). Impact of coronaphobia on treatment and follow-up compliance of cancer patients. Future Oncology.

6. Arıcı, S., Sağlampınar Karyağar, S., Uslu Erdemir, R., Çekin, R., Atcı, M. M., Güven, O., Karyağar, S., Cihan, Ş. (2021). The correlation between tumor markers and Ga-68 DOTA-TATE PET/CT findings in patients with advanced medullary thyroid cancer. Revista Española de Medicina Nuclear e Imagen Molecular.

7. Atcı, M. M., Gerede, Ç., Ay Ersoy, S., Ertürk, B., Seçmeler, Ş., Arıcı, S., Çekin, R., Yaşar, N., Can, O., Cihan, Ş., Gümüş, M. (2021). Clinical and pathological characteristics of patients with high-risk breast cancer based on BRCA mutation profiles: A retrospective study. European Journal of Breast Health.

8. Calm, A., Atcı, M. M., Aldemir, M. N., Akagündüz, B., Şahin, S., Arıcı, S., Seçmeler, Ş., Cihan, Ş. (2021). The prognostic value of postoperative lymph node ratio in neoadjuvant-treated gastric adenocarcinoma patients. Cureus.

9. Calm, A., Şahin, S., Sağlampınar Karyağar, S., Karyağar, S., Atcı, M. M., Akbörü, M. H., Cihan, Ş. (2021). The predictive value of baseline volumetric PET/CT parameters on treatment response and prognosis in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Journal of Gastrointestinal Cancer.

10. Arıcı, S., Şengiz Erhan, S., Geredeli, Ç., Atcı, M. M., Seçmeler, Ş., Çekin, R., Sakin, A., Cihan, Ş. (2021). The prognostic importance of microsatellite instability status in Turkish stage II and III gastric cancer patients who received adjuvant chemotherapy. International Journal of Hematology and Oncology.

11. Calm, A., Şahin, S., Atcı, M. M., Ayşegül, P., Yaşar, N., Geredeli, Ç., Aksaray, F., Cihan, Ş. (2021). The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer. Pulmonology.

12. Ayşegül, P., Şahin, S., Abdullah, P., Atcı, M. M., Geredeli, Ç., Cihan, Ş. (2021). Effect of type 2 diabetes mellitus on survival in metastatic pancreatic cancer. Journal of Surgery and Medicine (JOSAM).

13. Akagündüz, B., Akın Telli, T., Yıldırım, H. Ç., Sezgin Göksu, S., Demir, N., Hafızoğlu, E., Özer, M., Çevik, G. T., Sakin, A., Göktaş, A. S., Şengül Samancı, N., Özyurt, N., Atcı, M. M., Ayhan, M., Turan, M., Sarıyar, N., Karaçin, C., Kılıçkap, S., Paydaş, S., Doğan, M. (2021). Factors affecting survival in retroperitoneal sarcomas treated with upfront surgery: A real-world study by Turkish Oncology Group. International Journal of Hematology and Oncology.

14. Calm, A., Şahin, S., Atcı, M. M., Yaşar, N., Demir, C., Geredeli, Ç., Sakin, A., Cihan, Ş. (2020). The effect of body mass index on treatment outcomes in patients with metastatic non-small cell lung cancer treated with platinum-based therapy. Nutrition and Cancer.

15. Ayşegül, P., Şahin, S., Abdullah, P., Atcı, M. M., Yaşar, N., Arıcı, S., Geredeli, Ç., Karataş, F., Cihan, Ş. (2020). Assessment of pre-treatment albumin-bilirubin grade in pancreatic cancer patients with liver metastases. Journal of BUON.

16. Abdullah, P., Süleyman, Ş., Ayşegül, P., Atcı, M. M., Serdar, A., Yaşar, N., Demir, C., Geredeli, Ç., Cihan, Ş. (2020). Factors affecting survival in operated pancreatic cancer; Does tumor localization have a significant effect on treatment outcomes? Northern Clinics of Istanbu.

17. Arıcı, S., Sağlampınar Karyağar, S., Karyağar, S., Geredeli, Ç., Çekin, R., Seçmeler, Ş., Atcı, M. M., Sakin, A., Cihan, Ş. (2020). The predictive role of metabolic tumor volume on non-response to neoadjuvant chemotherapy in patients with breast cancer. Journal of Oncology Pharmacy Practice.

18. Calm, A., Yılmaz, Y., Şahin, S., Atcı, M. M., Arıcı, S., Geredeli, Ç., Yaşar, N., Demir, C., Cihan, Ş. (2020). Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience. Northern Clinics of Istanbul.

19. Calm, A., Şahin, S., Atcı, M. M., Yaşar, N., Geredeli, Ç., Arıbal, S., Alemdar, A., Karataş, F., Cihan, Ş. (2019). Factors affecting survival in patients with isolated liver-metastatic colorectal cancer treated with local ablative or surgical treatments for liver metastasis. Journal of BUON.

Das könnte Sie auch interessieren

Bezahlung und Belohnungen

Sie zahlen nicht für unsere Dienstleistungen

Sie zahlen direkt in der Klinik oder auf deren offizielles Bankkonto.

Sichere Buchung

Einige Kliniken können eine Anzahlung als Teil ihrer Police verlangen.

Flexible Raten

Verteilen Sie Ihre Zahlungen mit Ratenzahlungsoptionen.

Empfehlungsprogramm

Laden Sie Freunde zu Bookimed ein und erhalten Sie Belohnungen.